Literature DB >> 28168674

Clinical Implications of Biliary Confluence Pattern for Bismuth-Corlette Type IV Hilar Cholangiocarcinoma Applied to Hemihepatectomy.

Gu-Wei Ji1, Fei-Peng Zhu2, Ke Wang1, Chen-Yu Jiao1, Zi-Cheng Shao1, Xiang-Cheng Li3.   

Abstract

BACKGROUND: Since biliary variations are commonly seen, our aims are to clarify these insidious variations and discuss their surgicopathologic implications for Bismuth-Corlette (BC) type IV hilar cholangiocarcinoma (HC) applied to hemihepatectomy.
METHODS: Three-dimensional images of patients with distal bile duct obstruction (n = 97) and advanced HC (n = 79) were reconstructed and analyzed retrospectively. Normal biliary confluence pattern was defined as the peripheral segment IV duct (B4) joining the common trunk of segment II (B2) and segment III (B3) ducts to form the left hepatic duct (LHD) that then joined the right hepatic duct (RHD). The lengths from left and right secondary biliary ramifications to the right side of the umbilical portion of the left portal vein (Rl-L) and the cranio-ventral side of the right portal vein (Rr-R) were measured, respectively, and compared with the resectable bile duct length in HCs. Surgicopathologic findings were compared between different BC types.
RESULTS: The resectable bile duct length in right hemihepatectomy for eradication of type IV tumors was significantly longer than the Rl-L length in normal biliary configuration (17.4 ± 1.8 and 10.3 ± 3.4 mm, respectively, p < 0.001), and type III variation (B2 joining the common trunk of B3 and B4) was the predominant configuration (53.8%). The resectable length in left hemihepatectomy for eradication of type IV tumors was comparable with the Rr-R length in RHD absent cases (15.2 ± 2.5 and 16.4 ± 2.6 mm, respectively, p = 0.177) but significantly longer than that in normal configuration (p < 0.001). The estimated length was 8.5 ± 2.0 mm in unresectable cases. There was no significant difference between type III and IV tumors, except for the rate of nodal metastasis (29.7 and 76.0%, respectively, p < 0.001).
CONCLUSION: Hemihepatectomy might be selected for curative-intent resection of BC type IV tumors considering the advantageous biliary variations, whereas anatomical trisegmentectomy is recommended for the resectable bile duct length less than 10 mm. Biliary variations might result in excessive classification of BC type IV but require validation on further study.

Entities:  

Keywords:  Biliary variation; Bismuth-Corlette type IV; Hemihepatectomy; Hilar cholangiocarcinoma

Mesh:

Substances:

Year:  2017        PMID: 28168674     DOI: 10.1007/s11605-017-3377-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  32 in total

1.  Surgical and Radiological Studies on the Length of the Hepatic Ducts.

Authors:  Tomoaki Hirose; Tsuyoshi Igami; Tomoki Ebata; Yukihiro Yokoyama; Gen Sugawara; Takashi Mizuno; Kensaku Mori; Masahiko Ando; Masato Nagino
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

Review 2.  Bile duct confluence: anatomic variations and its classification.

Authors:  Eleazar Chaib; Alexandre Fligelman Kanas; Flavio Henrique Ferreira Galvão; Luiz Augusto Carneiro D'Albuquerque
Journal:  Surg Radiol Anat       Date:  2013-07-02       Impact factor: 1.246

3.  Imaging and surgical planning for perihilar cholangiocarcinoma.

Authors:  Itaru Endo; Ryusei Matsuyama; Ryutaro Mori; Koichi Taniguchi; Takafumi Kumamoto; Kazuhisa Takeda; Kuniya Tanaka; Alexander Köhn; Andrea Schenk
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-02-12       Impact factor: 7.027

4.  Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma.

Authors:  Peter Neuhaus; Armin Thelen; Sven Jonas; Gero Puhl; Timm Denecke; Wilfried Veltzke-Schlieker; Daniel Seehofer
Journal:  Ann Surg Oncol       Date:  2011-10-01       Impact factor: 5.344

5.  Pathological appraisal of lines of resection for bile duct carcinoma.

Authors:  T Ebata; H Watanabe; Y Ajioka; K Oda; Y Nimura
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

Review 6.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

7.  Biliary tract variations of the left liver with special reference to the left medial sectional bile duct in 500 patients.

Authors:  Norihiko Furusawa; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Keita Kanai; Norikazu Arakura; Akira Yamada; Yoshihiro Kitou; Shin-Ichi Miyagawa
Journal:  Am J Surg       Date:  2015-01-29       Impact factor: 2.565

Review 8.  Hilar cholangiocarcinoma: current management.

Authors:  Fumito Ito; Clifford S Cho; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

9.  Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.

Authors:  Hai-Jie Hu; Hui Mao; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

10.  Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas.

Authors:  T Ebata; T Kosuge; S Hirano; M Unno; M Yamamoto; M Miyazaki; N Kokudo; S Miyagawa; T Takada; M Nagino
Journal:  Br J Surg       Date:  2014-01       Impact factor: 6.939

View more
  7 in total

1.  Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma.

Authors:  Bei Li; Xian-Ze Xiong; Yong Zhou; Si-Jia Wu; Zhen You; Jiong Lu; Nan-Sheng Cheng
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

2.  Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases.

Authors:  Chihua Fang; Jihyun An; Antonio Bruno; Xiujun Cai; Jia Fan; Jiro Fujimoto; Rita Golfieri; Xishan Hao; Hongchi Jiang; Long R Jiao; Anand V Kulkarni; Hauke Lang; Cosmas Rinaldi A Lesmana; Qiang Li; Lianxin Liu; Yingbin Liu; Wanyee Lau; Qiping Lu; Kwan Man; Hitoshi Maruyama; Cristina Mosconi; Necati Örmeci; Michael Pavlides; Guilherme Rezende; Joo Hyun Sohn; Sombat Treeprasertsuk; Valérie Vilgrain; Hao Wen; Sai Wen; Xianyao Quan; Rafael Ximenes; Yinmo Yang; Bixiang Zhang; Weiqi Zhang; Peng Zhang; Shaoxiang Zhang; Xiaolong Qi
Journal:  Hepatol Int       Date:  2020-07-07       Impact factor: 6.047

3.  Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.

Authors:  Dingzhong Peng; Jiong Lu; Haijie Hu; Bei Li; Xiwen Ye; Nansheng Cheng
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

4.  Application of 3D visualization and 3D printing technology on ERCP for patients with hilar cholangiocarcinoma.

Authors:  Yan Yang; Zhongyin Zhou; Rong Liu; Lu Chen; Hongyu Xiang; Na Chen
Journal:  Exp Ther Med       Date:  2018-02-02       Impact factor: 2.447

5.  Comparison study for surgical outcomes of right versus left side hemihepatectomy to treat hilar cholangiocellular carcinoma.

Authors:  Seung Soo Hong; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi
Journal:  Ann Surg Treat Res       Date:  2019-12-30       Impact factor: 1.859

6.  Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics (HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study.

Authors:  Jia-Yun Lin; Chi-Hao Zhang; Lei Zheng; Hui-Song Chen; Hong-Jie Li; Yi-Ming Zhu; Xiao Fan; Feng Li; Yan Xia; Ming-Zhe Huang; Sun-Hu Yang; Xiao-Liang Qi; Hai-Zhong Huo; Xiao-Lou Lou; Meng Luo
Journal:  BMJ Open       Date:  2019-12-03       Impact factor: 2.692

7.  Assessment of a biofluid mechanics-based model for calculating portal pressure in canines.

Authors:  Jia-Yun Lin; Chi-Hao Zhang; Lei Zheng; Chen-Lu Song; Wen-Sheng Deng; Yi-Ming Zhu; Li Zheng; Li-Zhong Wu; Long-Ci Sun; Meng Luo
Journal:  BMC Vet Res       Date:  2020-08-26       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.